LU90011I2 - Remifentanil facultativement sous la forme d'un sel d'addition d'acide pharmaceutiquement acceptable y compris le chlorhydrate de remifentanil - Google Patents

Remifentanil facultativement sous la forme d'un sel d'addition d'acide pharmaceutiquement acceptable y compris le chlorhydrate de remifentanil

Info

Publication number: LU90011I2
Authority: LU; Luxembourg
Prior art keywords: lower alkyl; group; alkoxy; remifentanil; member selected
Prior art date: 1989-02-15

Application number

LU90011C

Other languages

English (en)

Original Assignee

Glaxo Wellcome Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-02-15

Filing date

1997-01-24

Publication date

1997-03-11

1997-01-24 Application filed by Glaxo Wellcome Inc filed Critical Glaxo Wellcome Inc

1997-03-11 Publication of LU90011I2 publication Critical patent/LU90011I2/fr

Links

239000002253 acid Substances 0.000 title abstract 2
150000003839 salts Chemical class 0.000 title abstract 2
ZTVQQQVZCWLTDF-UHFFFAOYSA-N Remifentanil Chemical compound C1CN(CCC(=O)OC)CCC1(C(=O)OC)N(C(=O)CC)C1=CC=CC=C1 ZTVQQQVZCWLTDF-UHFFFAOYSA-N 0.000 title 1
229960003394 remifentanil Drugs 0.000 title 1
WFBMIPUMYUHANP-UHFFFAOYSA-N remifentanil hydrochloride Chemical compound [Cl-].C1C[NH+](CCC(=O)OC)CCC1(C(=O)OC)N(C(=O)CC)C1=CC=CC=C1 WFBMIPUMYUHANP-UHFFFAOYSA-N 0.000 title 1
229960003011 remifentanil hydrochloride Drugs 0.000 title 1
125000000217 alkyl group Chemical group 0.000 abstract 7
150000001875 compounds Chemical class 0.000 abstract 3
230000000202 analgesic effect Effects 0.000 abstract 2
229910052739 hydrogen Inorganic materials 0.000 abstract 2
239000001257 hydrogen Substances 0.000 abstract 2
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
125000003545 alkoxy group Chemical group 0.000 abstract 1
125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 1
150000001408 amides Chemical class 0.000 abstract 1
230000036592 analgesia Effects 0.000 abstract 1
125000001475 halogen functional group Chemical group 0.000 abstract 1
150000002431 hydrogen Chemical class 0.000 abstract 1
239000000543 intermediate Substances 0.000 abstract 1
125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 abstract 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
-1 tri-substituted phenyl Chemical group 0.000 abstract 1
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
- C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pain & Pain Management (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biomedical Technology (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Hydrogenated Pyridines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

LU90011C 1989-02-15 1997-01-24 Remifentanil facultativement sous la forme d'un sel d'addition d'acide pharmaceutiquement acceptable y compris le chlorhydrate de remifentanil LU90011I2 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US31131189A	1989-02-15	1989-02-15
US07/448,497 US5019583A (en)	1989-02-15	1989-12-11	N-phenyl-N-(4-piperidinyl)amides useful as analgesics

Publications (1)

Publication Number	Publication Date
LU90011I2 true LU90011I2 (fr)	1997-03-11

Family

ID=26977841

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LU90011C LU90011I2 (fr)	1989-02-15	1997-01-24	Remifentanil facultativement sous la forme d'un sel d'addition d'acide pharmaceutiquement acceptable y compris le chlorhydrate de remifentanil

Country Status (22)

Country	Link
US (1)	US5019583A (fr)
EP (1)	EP0383579B1 (fr)
JP (1)	JP2895145B2 (fr)
KR (1)	KR0160979B1 (fr)
AT (1)	ATE140451T1 (fr)
AU (1)	AU636330B2 (fr)
CA (1)	CA2010011C (fr)
CY (1)	CY2002A (fr)
CZ (1)	CZ402591A3 (fr)
DE (2)	DE19675028I2 (fr)
DK (1)	DK0383579T3 (fr)
ES (1)	ES2088961T4 (fr)
GR (1)	GR3020719T3 (fr)
HK (1)	HK78297A (fr)
IE (1)	IE77156B1 (fr)
LU (1)	LU90011I2 (fr)
MX (1)	MX9203024A (fr)
NL (1)	NL960030I2 (fr)
NZ (1)	NZ232542A (fr)
PT (1)	PT93137B (fr)
SG (1)	SG47967A1 (fr)
SK (1)	SK402591A3 (fr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5214148A (en) *	1990-12-18	1993-05-25	Glaxo Inc.	Analgesic N-phenyl-N-(3-OR1 -3-ME-4-piperidinyl)amides
US5130321A (en) *	1990-12-18	1992-07-14	Glaxo Inc.	Analgesic n-phenyl-n-(3-or 1-3-me-4-piperidinyl)amides
GB9316863D0 (en) *	1993-08-13	1993-09-29	Glaxo Group Ltd	Chemical process
US5466700A (en) *	1993-08-30	1995-11-14	Glaxo Wellcome Inc.	Anesthetic use of N-phenyl-N-(4-piperidinyl)amides
US5866591A (en) *	1996-09-11	1999-02-02	Glaxo Wellcome Inc.	Stable formulations of remifentanil
JP4754068B2 (ja) *	1997-12-24	2011-08-24	オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド	δ−オピオイドレセプターに結合する４−［アリール（ピペリジン−４−イル）］アミノベンズアミド類
US6858018B1 (en)	1998-09-28	2005-02-22	Vyteris, Inc.	Iontophoretic devices
US6436959B1 (en)	1998-12-23	2002-08-20	Ortho-Mcneil Pharmaceutical, Inc.	4-[aryl(piperidin-4-yl)]aminobenzamides
CA2393559C (fr)	1999-12-06	2009-05-26	Mallinckrodt Inc.	Nouvelles methodes de synthese d'alfentanil, de sufentanil et de remifentanil
US6476050B2 (en)	2000-03-14	2002-11-05	Sepracor, Inc.	3-substituted piperidines comprising urea functionality, and methods of use thereof
SI1307194T2 (sl) *	2000-07-31	2011-07-29	Nycomed Danmark Aps	Sestavek fentanila za nazalno dejanje
EP1414798A2 (fr) *	2001-04-03	2004-05-06	Aryx Therapeutics	Opioides a action ultrabreve pour application transdermique
EP1455784A1 (fr) *	2001-12-17	2004-09-15	Aryx Therapeutics	Systemes d'administration d'analgesiques et methodes d'utilisation
JPWO2005030722A1 (ja) *	2003-09-29	2006-12-07	日本ケミファ株式会社	Ｎ−置換−ｎ−（４−ピペリジニル）アミド誘導体
JP2008502651A (ja)	2004-06-18	2008-01-31	ノイロサーチアクティーゼルスカブ	モノアミン神経伝達物質再取込み阻害剤としての、新規アルキル置換ピペリジン誘導体及びその使用
US20090030041A1 (en) *	2004-09-14	2009-01-29	Toshihiro Takahashi	N-substituted N-(4-piperidinyl) Amide Derivative
WO2007061555A1 (fr) *	2005-11-17	2007-05-31	Mallinckrodt Inc.	Procede de synthetisation du remifentanil
EP1984336A2 (fr) *	2006-01-24	2008-10-29	Mallinckrodt, Inc.	Procédé de synthèse de rémifentanil
CA2641283A1 (fr) *	2006-02-03	2007-08-16	Mallinckrodt Inc.	Forme cristalline d'hydrochlorure de remifentanil
EP1867635A1 (fr) *	2006-06-15	2007-12-19	Kern Pharma, S.L.	Procédé de préparation de remifentanil, ses produits intermédiaires, leur application et procédé pour leur préparation
DE602007009128D1 (de) *	2006-07-10	2010-10-21	Paion Uk Ltd	Benzodiazepinsalze mit kurzzeitwirkung und polymorphe formen davon
GB0613693D0 (en) *	2006-07-10	2006-08-16	Cenes Ltd	Benzodiazepine salts (3)
US20100099880A1 (en) *	2006-10-05	2010-04-22	Brian Cheng	Alternate Process for Remifentanil Preparation
US20100048908A1 (en) *	2006-11-29	2010-02-25	Brian Kai-Ming Cheng	Process for Remifentanil Synthesis
US8557856B2 (en)	2008-03-31	2013-10-15	The General Hospital Corporation	Etomidate analogues with improved pharmacokinetic and pharmacodynamic properties
JP2011526257A (ja) *	2008-07-03	2011-10-06	シラグアーゲー	Ｎ−フェニル−ｎ−（４−ピペリジニル）アミド塩の製造方法
US8299258B2 (en) *	2008-11-04	2012-10-30	Cambrex Charles City	Method of making piperidine derivatives
RU2559888C2 (ru)	2009-07-10	2015-08-20	Зе Дженерал Хоспитал Корпорэйшн	Аналоги этомидата, которые не ингибируют синтез адренокортикостероидов
EP2450039A1 (fr)	2010-11-08	2012-05-09	PAION UK Ltd.	Régime de dosage permettant la sédation avec CNS 7056 (Remimazolam)
JP6196986B2 (ja)	2012-01-13	2017-09-13	ザジェネラルホスピタルコーポレイション	麻酔化合物および関連する使用方法
JP6309957B2 (ja)	2012-10-08	2018-04-11	オークランドユニサービシーズリミティド	ケタミン誘導体
AR094963A1 (es)	2013-03-04	2015-09-09	Ono Pharmaceutical Co	Reacción de oxidación excelente en el índice de conversión
CN103728403B (zh) *	2013-08-30	2015-10-07	宜昌人福药业有限责任公司	一种盐酸瑞芬太尼原料药中有关物质的检测方法
SI3199523T1 (sl)	2016-01-29	2018-12-31	Bioka S.R.O.	Nov postopek za pridobivanje n-fenil-n-(4-piperinidil)amidnih derivatov kot sta remifentanil in karfentanil
ES2858404T3 (es)	2018-10-26	2021-09-30	Hameln Pharma Gmbh	Nuevos intermedios para la preparación de clorhidrato de remifentanilo
GB202010168D0 (en) *	2020-07-02	2020-08-19	Johnson Matthey Plc	Process for preparing remifentanil hydrochloride
CN114262320A (zh) *	2021-12-28	2022-04-01	宜昌人福药业有限责任公司	一种利用连续流微通道反应器制备苯胺基哌啶类药物的合成方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BE623427A (fr) *	1961-10-10
US3655675A (en) *	1968-09-09	1972-04-11	Sterling Drug Inc	N-(n-heteryl)-acylanilides
US4179569A (en) *	1975-03-14	1979-12-18	Janssen Pharmaceutica N.V.	N-(4-piperidinyl)-N-phenylamides
US3998834A (en) *	1975-03-14	1976-12-21	Janssen Pharmaceutica N.V.	N-(4-piperidinyl)-n-phenylamides and -carbamates
US4167574A (en) *	1978-03-13	1979-09-11	Janssen Pharmaceutica, N.V.	N-phenyl-N-(4-piperidinyl)amides
US4584303A (en) *	1984-04-09	1986-04-22	The Boc Group, Inc.	N-aryl-N-(4-piperidinyl)amides and pharmaceutical compositions and method employing such compounds
US4801721A (en) *	1984-08-16	1989-01-31	Ryan James W	Stereospecific synthesis of carboxyalkyl peptides
CA1317940C (fr) *	1987-09-25	1993-05-18	Georges H. P. Van Daele	N-(1-alkyl-3-hydroxy-4-piperidinyl) benzamides a substituant

1989
- 1989-12-11 US US07/448,497 patent/US5019583A/en not_active Expired - Lifetime
1990
- 1990-02-14 DE DE1996175028 patent/DE19675028I2/de active Active
- 1990-02-14 AT AT90301586T patent/ATE140451T1/de active
- 1990-02-14 AU AU49731/90A patent/AU636330B2/en not_active Expired
- 1990-02-14 PT PT93137A patent/PT93137B/pt not_active IP Right Cessation
- 1990-02-14 DE DE69027794T patent/DE69027794T2/de not_active Expired - Lifetime
- 1990-02-14 JP JP2031680A patent/JP2895145B2/ja not_active Expired - Lifetime
- 1990-02-14 KR KR1019900001796A patent/KR0160979B1/ko not_active Expired - Lifetime
- 1990-02-14 SG SG1996005735A patent/SG47967A1/en unknown
- 1990-02-14 IE IE53290A patent/IE77156B1/en not_active IP Right Cessation
- 1990-02-14 ES ES90301586T patent/ES2088961T4/es not_active Expired - Lifetime
- 1990-02-14 DK DK90301586.5T patent/DK0383579T3/da active
- 1990-02-14 NZ NZ232542A patent/NZ232542A/en unknown
- 1990-02-14 EP EP90301586A patent/EP0383579B1/fr not_active Expired - Lifetime
- 1990-02-14 CA CA002010011A patent/CA2010011C/fr not_active Expired - Fee Related
1991
- 1991-12-23 SK SK4025-91A patent/SK402591A3/sk unknown
- 1991-12-23 CZ CS914025A patent/CZ402591A3/cs unknown
1992
- 1992-06-19 MX MX9203024A patent/MX9203024A/es unknown
1996
- 1996-08-02 GR GR960402083T patent/GR3020719T3/el unknown
- 1996-11-21 NL NL960030C patent/NL960030I2/nl unknown
1997
- 1997-01-24 LU LU90011C patent/LU90011I2/fr unknown
- 1997-06-12 HK HK78297A patent/HK78297A/en not_active IP Right Cessation
- 1997-12-05 CY CY200297A patent/CY2002A/xx unknown

Also Published As

Publication number	Publication date
NZ232542A (en)	1992-06-25
US5019583A (en)	1991-05-28
EP0383579A1 (fr)	1990-08-22
DE19675028I2 (de)	2002-11-07
CA2010011A1 (fr)	1990-08-15
IE77156B1 (en)	1997-12-03
JPH02300167A (ja)	1990-12-12
ATE140451T1 (de)	1996-08-15
DE69027794D1 (de)	1996-08-22
NL960030I1 (nl)	1997-02-03
IE900532L (en)	1990-08-15
NL960030I2 (nl)	1997-05-01
DK0383579T3 (da)	1996-10-14
KR0160979B1 (ko)	1998-12-01
AU636330B2 (en)	1993-04-29
JP2895145B2 (ja)	1999-05-24
KR900012906A (ko)	1990-09-03
PT93137B (pt)	1996-02-29
SG47967A1 (en)	1998-04-17
CY2002A (en)	1997-12-05
SK402591A3 (en)	2000-09-12
CZ402591A3 (en)	1993-04-14
GR3020719T3 (en)	1996-11-30
HK78297A (en)	1997-06-20
DE69027794T2 (de)	1997-01-02
ES2088961T3 (es)	1996-10-01
CA2010011C (fr)	1997-12-02
EP0383579B1 (fr)	1996-07-17
AU4973190A (en)	1990-08-23
MX9203024A (es)	1992-07-01
ES2088961T4 (es)	1996-12-01
PT93137A (pt)	1990-08-31

Publication	Publication Date	Title
LU90011I2 (fr)	1997-03-11	Remifentanil facultativement sous la forme d'un sel d'addition d'acide pharmaceutiquement acceptable y compris le chlorhydrate de remifentanil
LU90160I2 (fr)	1998-01-14	Naratriptan facultativement sous la forme d'un sel pharmaceutiquement acceptable ou d'un solvate y compris le chlorhydrate de naratriptan
ATE33835T1 (de)	1988-05-15	Verbindung mit antibronchopneumopathischer wirkung, verfahren zur herstellung und sie enthaltende pharmazeutische zusammensetzungen.
KR960037675A (ko)	1996-11-19	벤조니트릴 및 벤조플루오라이드
EP0353955A3 (fr)	1991-08-14	Composés chimiques
MA27197A1 (fr)	2005-01-03	Sels de tolterodine
FI860878A0 (fi)	1986-03-03	Aminosyraderivat och foerfarande foer deras framstaellning.
CA2406266A1 (fr)	2001-10-25	Derive de pyridine-1-oxyde, et processus de transformation de ce derive en composes pharmaceutiquement efficace
DK26289D0 (da)	1989-01-20	Anvendelse af 1,4-disubstitueret piperidinyl til fremstilling af et farmaceutisk praeparat til behandling af insomnia
PT90725A (pt)	1989-12-29	Processo para a preparacao de novos compostos cefem
FI933719A0 (fi)	1993-08-24	4-((2-bensotiazolyl)metylamino)-a-((3,4-difluorfenoxi)metyl)-1-piperidinetanol
ES2114722T3 (es)	1998-06-01	Procedimiento para preparar intermedios derivados del acido benzoico y agentes farmaceuticos benzotiofenos.
KR20210121989A (ko)	2021-10-08	베타코로나바이러스 감염을 예방하기 위한 조성물
SE9900190D0 (sv)	1999-01-22	New compounds
DE69001004D1 (de)	1993-04-08	Zusammensetzung gegen leberkrankheiten.
JPS5585550A (en)	1980-06-27	4-homoisotwistane amino acid amide
TH20641A (th)	1996-09-17	6-[ไทรแอโซลิล[3-(ไทรฟลูออโรเมธิล)เฟนิล]เมธิล]-2-ควิโนลิโนนและ-ควิโนลีนไธโอน
SE9904416D0 (sv)	1999-12-03	Crystalline form
DK0420464T3 (da)	1994-11-07	3-isoxazolonderivater, deres fremstilling af deres terapeutiske anvendelser